-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Raises Price Target to $27

Benzinga·11/16/2026 15:19:53
Listen to the news
Morgan Stanley analyst Judah Frommer maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Equal-Weight and raises the price target from $26 to $27.